Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8(+)-T cell immunity

BACKGROUND: The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slight...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feng, Zhou, Qian, Jiang, Hai-feng, Zhang, Ting-ting, Miao, Cheng, Xu, Xiao-hong, Wu, Jia-xing, Yin, Song-lin, Xu, Shi-jie, Peng, Jing-yi, Gao, Pan-pan, Cao, Xuan, Pan, Feng, He, Ximiao, Chen, Xiao Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170830/
https://www.ncbi.nlm.nih.gov/pubmed/37161450
http://dx.doi.org/10.1186/s13046-023-02686-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170830/
https://www.ncbi.nlm.nih.gov/pubmed/37161450
http://dx.doi.org/10.1186/s13046-023-02686-1

Ejemplares similares